20 Sep 2011

Yungjin pharm. signed the technique export and supply contract with China MEHECO for Yungjin Opast (limaprost alfadex), used to treat spinal stenosis, on 19^th sep. 2011.

Limaprost has antiplatelet, vasodilating action which improves ischemic symptoms such as ulcer, pain and coldness accompanied by thromboangiitis obliterans. Moreover it improves subjective symptoms and gait ability, accompanied by acquired spinal stenosis.

Yungjin developed its own innovative formulation technology that “improved the problem of vulnerability to moisture and made drug intake more convenient with most convenient drug intake” which is better than the existing formulation technology.

Yungjin offered exclusive sales rights to China MEHECO where Yungjin will supply minimum of 13million dollars worth bulk products to MEHECO in the technique export and supply contract.  

Yungjin released the limaprost formulation “Opast tablet” this June and has the ambition to make it an annual sale of 10 million dollars product.

Yungjin achieved another splendid accomplishment with the exceptional formulation technology for limaprost following signing of Cefcapene tablet antibiotics supply contract with Shenzhen Zhijun Medical & Pharmaceuticals Trading this July, allowing Yungjin to go forward with China exportation.

Moreover “Yungjin is increasing overseas exportation proportion. Yungjin is aiming to become global company by continuous R&D and overseas business expansion and China exportation is the steppingstone especially”.